Immutep Limited Faces Class Action Lawsuit for Securities Violations
Immutep Limited Faces Legal Challenges Over Securities Violations
Immutep Limited, a biotechnology company listed on NASDAQ under the ticker symbol IMMP, is facing a class action lawsuit initiated by the DJS Law Group. This legal action highlights potential violations of the Securities Exchange Act of 1934, specifically related to misleading statements made to investors during a particular class period. The lawsuit has garnered attention from shareholders who are concerned about their investments in the company.
Details of the Lawsuit
The class period in question spans from March 24, 2025, to March 12, 2026. It has been alleged that Immutep issued false and misleading statements regarding the outcomes of its clinical trial, TACTI-004, which involved the treatment known as eftilagimod alfa (commonly referred to as 'efti'). On January 30, 2026, Immutep announced that the trial was showing
Topics Other）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.